NLY 12
Alternative Names: NLY-12Latest Information Update: 14 Apr 2023
At a glance
- Originator Neuraly
- Developer D and D Pharmatech; Neuraly
- Class Antihypercalcaemics; Obesity therapies
- Mechanism of Action Glucagon-like peptide-1 receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Obesity; Type 2 diabetes mellitus
Most Recent Events
- 04 Apr 2023 Preclinical trials in Obesity in USA (unspecified route) (D and D Pharmatech pipeline, April 2023)
- 04 Apr 2023 Preclinical trials in Type 2 diabetes mellitus in USA (unspecified route) (D and D Pharmatech pipeline, April 2023)